Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Current Investments: 2014-2025

Historic Cash & Current Investments for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $329.7 million.

  • Theravance Biopharma's Cash & Current Investments rose 260.85% to $329.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $887.7 million, marking a year-over-year increase of 127.71%. This contributed to the annual value of $88.3 million for FY2024, which is 13.74% down from last year.
  • Theravance Biopharma's Cash & Current Investments amounted to $329.7 million in Q3 2025, which was down 2.69% from $338.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Cash & Current Investments registered a high of $486.8 million during Q3 2022, and its lowest value of $88.3 million during Q4 2024.
  • Over the past 3 years, Theravance Biopharma's median Cash & Current Investments value was $130.9 million (recorded in 2025), while the average stood at $165.5 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 72.47% in 2023, then soared by 260.85% in 2025.
  • Over the past 5 years, Theravance Biopharma's Cash & Current Investments (Quarterly) stood at $173.5 million in 2021, then spiked by 88.79% to $327.5 million in 2022, then plummeted by 68.72% to $102.4 million in 2023, then fell by 13.74% to $88.3 million in 2024, then soared by 260.85% to $329.7 million in 2025.
  • Its last three reported values are $329.7 million in Q3 2025, $338.8 million for Q2 2025, and $130.9 million during Q1 2025.